Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/Tazobactam Plus Metronidazole vs Meropenem in cIAI
NCT03830333Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Intra-abdominal infection (IAI) comparing Ceftolozane/Tazobactam + Metronidazole with Meropenem + Placebo (2 arms). Primary endpoint: Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit at Day 30. Started Mar 2019; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT03830333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03830333.